Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 9/20 | 0.52 |
| ▸ | CNR2 | P34972 | 9/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | MTOR | P42345 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | RGS12 | O14924 | 1/20 | 0.49 |
| ▸ | GMNN | O75496 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.49 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | THPO | P40225 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4089479 | 1.00 | CNR1 (0.52) | CNR1CNR2ALDH1A1MAPTNPC1 | |
| SCHEMBL31318122 | 1.00 | CNR1 (0.52) | CNR1CNR2ALDH1A1MAPTNPC1 | |
| SCHEMBL5792357 | 0.96 | CNR1 (0.55) | CNR1CNR2ALDH1A1MAPTNPC1 | |
| SCHEMBL31318123 | 0.96 | CNR1 (0.55) | CNR1CNR2ALDH1A1MAPTNPC1 | |
| SCHEMBL3011354 | 0.96 | CNR1 (0.55) | CNR1CNR2ALDH1A1MAPTNPC1 | |
| SCHEMBL7024508 | 0.78 | CNR1 (0.42) | CNR1CNR2ALDH1A1MAPTNPC1 | |
| SCHEMBL4089485 | 0.78 | SSTR4 (0.35) | CNR1CNR2ALDH1A1MAPTNPC1 | |
| SCHEMBL5792354 | 0.75 | ALDH1A1 (0.38) | CNR1CNR2ALDH1A1MAPTNPC1 | |
| SCHEMBL17237462 | 0.75 | ALDH1A1 (0.38) | CNR1CNR2ALDH1A1MAPTNPC1 | |
| SCHEMBL9700462 | 0.70 | CNR1 (0.66) | CNR1CNR2ALDH1A1MAPTNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020077322-A1 | Protection of neurons against glutamate-induced damage in glaucoma and other conditions | AYOUB GEORGE S (US) | 2002-06-20 | — | — | US | claimed |
| EP-1919471-B1 | (INDOL-3-YL)-HETEROCYCLE DERIVATIVES AS AGONISTS OF THE CANNABINOID CB1 RECEPTOR | MERCK SHARP & DOHME (NL) | 2014-01-08 | — | — | EP | disclosed |
| EP-2125795-B1 | INDOLE DERIVATIVES | MSD OSS BV (NL) | 2013-03-20 | — | — | EP | disclosed |
| US-7772227-B2 | Tricyclic 1-[(indol-3-yl)carbonyl]piperazine derivatives as cannabinoid CB1 receptor agonists | N.V. ORGANON (NL) | 2010-08-10 | — | — | US | disclosed |
| US-7763732-B2 | 7-Chloro-3-({5-[N-(morpholin-1-ylcarboxamido)methyl]aminomethyl}-([1,2,4]-thiadiazol-3-yl))-1-(tetrahydropyran-4-yl)methyl-1H-indole, hydrochloride salt; treatment of pain | N.V. ORGANON (NL) | 2010-07-27 | — | — | US | disclosed |
| US-7700634-B2 | (Indol-3-yl) heterocycle derivatives as agonists of the cannabinoid CB1 receptor | N.V. ORGANON (NL) | 2010-04-20 | — | — | US | disclosed |
| US-7655645-B2 | Analgesics; neuropathic pain, cancer pain, multiple sclerosis | N.V. ORGANON (NL) | 2010-02-02 | — | — | US | disclosed |
| US-20090275649-A1 | Compositions And Methods For Identifying Modulars Of TRPV2 | QIN NING | 2009-11-05 | — | — | US | disclosed |
| US-20090275649-A1 | Compositions And Methods For Identifying Modulars Of TRPV2 | QIN NING | 2009-11-05 | — | — | US | disclosed |
| US-7575882-B2 | Compositions and methods for identifying modulators of TRPV2 | JANSSEN PHARMACEUTICA N. V. (BE) | 2009-08-18 | — | — | US | disclosed |
| US-20080207598-A1 | INDOLE DERIVATIVES | N.V. ORGANON (NL) | 2008-08-28 | — | — | US | disclosed |
| EP-1725232-B1 | (INDOL-3-YL)-HETEROCYCLE DERIVATIVES AS AGONISTS OF THE CANNABINOID CB1 RECEPTOR | ORGANON NV (NL) | 2008-01-23 | — | — | EP | disclosed |
| US-20070142446-A1 | (Indol-3-yl) heterocycle derivatives as a agonists of the cannabinoid cb1 receptor | MERCK SHARP & DOHME B.V. (NL) | 2007-06-21 | — | — | US | disclosed |
| US-20070105086-A1 | Compositions and methods for identifying modulators of TRPV2 | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-05-10 | — | — | US | disclosed |
| US-20070105086-A1 | Compositions and methods for identifying modulators of TRPV2 | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-05-10 | — | — | US | disclosed |
| US-20070088025-A1 | such as (R)-3-Cyclohexyl-2,3-dihydro-6-(4-ethylpiperazin-1-ylcarbonyl)pyrrolo[1,2,3-de]-1,4-benzoxazine hydrochloride salt, used as analgesics for the treatment of post-operative pain, chronic pain neuropathic pain, cancer pain and spasticity associated with multiple sclerosis | AKZO NOBEL N.V. (NL) | 2007-04-19 | — | — | US | disclosed |
| EP-1696930-B1 | TRICYCLIC 1-((3-INDOL-3-YL)CARBONYL)PIPERAZINE DERIVATIVES AS CANNABINOID CB1 RECEPTOR AGONISTS | ORGANON NV (NL) | 2007-04-11 | — | — | EP | disclosed |
| US-20070072096-A1 | Negative curable dye-containing composition, color filter, and method of manufacturing the same | FUJI PHOTO FILM CO., LTD. | 2007-03-29 | — | — | US | disclosed |
| WO-2002047691-A9 | PROTECTION OF NEURONS AGAINST GLUTAMATE-INDUCED DAMAGE IN GLAUCOMA AND OTHER CONDITIONS | AYOUB GEORGE S (US) | 2003-11-20 | — | — | WO | disclosed |
| WO-2002047691-A1 | PROTECTION OF NEURONS AGAINST GLUTAMATE-INDUCED DAMAGE IN GLAUCOMA AND OTHER CONDITIONS | AYOUB GEORGE S (US) | 2002-06-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207598-A1 | INDOLE DERIVATIVES | CNR1, CNR2, OPRD1 | CNR1 1/4885CNR2 2/4885ALDH1A1 4175/4885 |
| US-20070142446-A1 | (Indol-3-yl) heterocycle derivatives as a agonists of the cannabinoid cb1 receptor | CNR1, CNR2, OPRL1 | CNR1 1/4885CNR2 2/4885ALDH1A1 1616/4885 |
| US-20070088025-A1 | such as (R)-3-Cyclohexyl-2,3-dihydro-6-(4-ethylpiperazin-1-ylcarbonyl)pyrrolo[1,2,3-de]-1,4-benzoxazine hydrochloride salt, used as analgesics for the treatment of post-operative pain, chronic pain neuropathic pain, cancer pain and spasticity associated with multiple sclerosis | OPRD1, OPRK1, OPRM1 | CNR1 4/4885CNR2 6/4885ALDH1A1 2439/4885 |
| US-20090275649-A1 | Compositions And Methods For Identifying Modulars Of TRPV2 | TRPV2, TRPV1, TRPV3 | CNR1 21/4885CNR2 8/4885ALDH1A1 4776/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.